Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Genetesis, founded in 2013 and headquartered in Mason, Ohio, is a medical imaging company specializing in cardiovascular health. The company's flagship product, CardioFlux, is a non-invasive magnetocardiography (MCG) device that detects myocardial ischemia without radiation, offering rapid and dynamic cardiac imaging. Genetesis primarily serves the healthcare sector, focusing on emergency medicine and cardiology.
Since its inception, Genetesis has raised a total of $36.13 million in funding, demonstrating investor confidence in its innovative technology. The company's unique approach to cardiac imaging positions it as a potential disruptor in the medical device industry, which may attract attention from both investors and industry observers.
As of now, there is no concrete information available regarding Genetesis' plans for an initial public offering (IPO). The company has not made any official announcements about going public, and we have not found any credible reports or rumors suggesting an imminent IPO.
Factors that could influence Genetesis' decision to go public in the future may include market conditions in the healthcare and medical device sectors, the company's financial performance, and its growth trajectory. However, without official statements from the company or reliable industry sources, any discussion of a potential Genetesis IPO remains speculative at this time.
Investors interested in the medical imaging and cardiovascular health sectors should continue to monitor Genetesis' progress and any official announcements regarding its future plans. As always, it's important to conduct thorough research and consider multiple factors before making investment decisions.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Genetesis's IPO prospects remain uncertain, investors interested in innovative medical technology companies don't have to wait. At Linqto, we offer members access to interests in promising pre-IPO private companies like Genetesis. Our platform allows you to diversify your portfolio with lower minimum investments in potential industry leaders, giving you the opportunity to benefit from their growth before they go public. Explore our selection of high-potential private companies in the healthcare and technology sectors today.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
